Your browser doesn't support javascript.
loading
New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics.
Sardi, S Pablo; Simuni, Tanya.
Affiliation
  • Sardi SP; Neuroscience Therapeutic Area, Sanofi, Framingham, MA, USA. Electronic address: Pablo.sardi@sanofi.com.
  • Simuni T; Northwestern University Feinberg School of Medicine, USA. Electronic address: tsimuni@nm.org.
Parkinsonism Relat Disord ; 59: 32-38, 2019 02.
Article in En | MEDLINE | ID: mdl-30391183
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Biological Therapy / Alpha-Synuclein / Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 / Glucosylceramidase Limits: Humans Language: En Journal: Parkinsonism Relat Disord Journal subject: NEUROLOGIA Year: 2019 Document type: Article Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Biological Therapy / Alpha-Synuclein / Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 / Glucosylceramidase Limits: Humans Language: En Journal: Parkinsonism Relat Disord Journal subject: NEUROLOGIA Year: 2019 Document type: Article Country of publication: United kingdom